Generate Biomedicines, Inc.

424B4 priced

Price $16.00 · 25,000,000 shares · Gross proceeds $400,000,000

Generate Biomedicines, Inc. is conducting its initial public offering (IPO) of 25,000,000 shares of common stock at $16.00 per share, with proceeds totaling $374 million. The company, a clinical-stage generative biology firm, aims to leverage AI-driven drug design through its proprietary Generate Platform. The shares will be listed on Nasdaq under the symbol 'GENB,' and the offering includes an underwriter option to purchase additional shares. The company emphasizes its focus on programmable biology and advanced therapeutic candidates, including GB-0895, which is in Phase 3 trials for severe asthma.

EFFECT effective

Generate Biomedicines, Inc. has filed an S-1 registration statement for its IPO, effective February 26, 2026. The filing confirms the registration of common stock for trading on The Nasdaq Stock Market LLC, following an earlier 8-A12B submission on February 24, 2026, which outlined the company's intent to register securities under Section 12(b) of the Securities Exchange Act.

CERT inactive

The current filing is a CERT form for Generate Biomedicines, Inc., dated 2026-02-26, following a previous EFFECT form. The text appears corrupted or non-readable, preventing detailed analysis. The previous filing confirmed effectiveness of an S-1 registration statement, typical for IPO preparations.

8-A12B effective

Generate Biomedicines, Inc. filed Form 8-A12B to register its common stock for listing on Nasdaq under the symbol 'GENB.' The filing references the previously filed S-1/A registration statement, indicating the company is proceeding with its initial public offering. The company is a clinical-stage biotechnology firm leveraging AI for drug design, and the registration aligns with its IPO roadmap.

S-1/A amended

Range $15.00 to $17.00 · 25,000,000 shares · Gross proceeds $425,000,000

Generate Biomedicines, Inc. is conducting an initial public offering (IPO) of 25,000,000 shares of common stock, with an estimated price range of $15.00 to $17.00 per share. The company, a clinical-stage generative biology firm, leverages its AI-driven Generate Platform to design therapeutics for complex biological challenges. Its lead candidate, GB-0895, is in Phase 3 trials for severe asthma, with potential for quarterly dosing. The offering includes underwriters such as Goldman Sachs and Morgan Stanley, and the company plans to list on Nasdaq under 'GENB'.

S-1/A amended

Generate Biomedicines, Inc. filed an S-1/A registration statement to amend its initial IPO filing, primarily adding exhibits and updating corporate disclosures. The amendment focuses on regulatory compliance and preparatory documentation for the IPO, with no substantive changes to business operations or financials disclosed.

S-1 filed

Generate Biomedicines, Inc. is a clinical-stage biotechnology company leveraging AI for drug discovery and development. The company is conducting an initial public offering (IPO) of its common stock, with three computationally engineered proteins in clinical trials. The Generate Platform integrates AI and experimental systems to design and test therapeutic candidates, including GB-0895, an anti-TSLP monoclonal antibody in Phase 3 trials for severe asthma. The IPO aims to fund ongoing research, clinical trials, and commercialization efforts.

DRS filed

Generate Biomedicines, Inc. is a clinical-stage biotechnology company leveraging AI-driven generative biology to develop novel therapeutics. The company is conducting its initial public offering (IPO) of common stock, with shares expected to be listed on Nasdaq under the symbol 'GENB.' The offering is led by underwriters Goldman Sachs & Co. LLC and Morgan Stanley. Generate's platform integrates computational models with experimental systems to engineer therapeutic candidates, with three computationally designed proteins in clinical trials, including GB-0895 for severe asthma. The company is an emerging growth company and smaller reporting company under U.S. securities laws.